The dispute over the Medicare drug price negotiation program has moved from a war of words into the courtroom.

The U.S. Chamber of Commerce and the federal government on Friday presented oral arguments before U.S. District Judge Michael Newman in Dayton, Ohio. The program, which was established by the Inflation Reduction Act, aims to save $25 billion annually by 2031 through price negotiations for the drugs that are most costly to Medicare.

Attorney Jeffrey Bucholtz, representing the chamber, argued that the program violates drugmakers' due process rights by giving the government power to effectively dictate prices for their products. "There is a very, very high risk, maybe a guarantee, but certainly a very, very high risk, that this regime will result in prices that are unfair," he said.